Kaleo’s exciting new Allerject, an alternative to the EpiPen, faced enormous challenges: Canadian regulations forbade it from referencing its competitor by name. FCB Health Canada’s campaign focuses on the finding that 48% of users don’t carry their EpiPen — it’s bulky, cumbersome, indiscreet and confusing. In its first three months, Allerject wrestled a 10% market share from EpiPen.
Silver | Multichannel Campaign (Small to Medium Product Size), 2021
Kaleo, FCB Health Canada and Allerject, Fits Your Life
![](https://www.mmm-online.com/wp-content/uploads/sites/2/2021/10/Fits-Your-Life-01-1-860x606.jpg)